In the context of gut peptides, current anti‐obesity medications primarily involve drugs that target the incretin hormones glucagon‐like peptide‐1 (GLP‐1) and gastric inhibitory polypeptide (GIP).25, 26. This evidence concerns the gene GIP and obesity due to melanocortin 4 receptor deficiency.